- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04819490
A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH
A UK Multicentre, Non-interventional, Observational, Health-Related Quality of Life Study for Children and Adolescents With X-linked Hypophosphataemia
Study Overview
Status
Conditions
Detailed Description
This is a multicentre, non-interventional HRQoL study of children and adolescents with growing skeletons using routinely collected XLH Registry data and prospectively collected HRQoL data. This study will aim to enrol approximately 50 patients from approximately 5 UK centres (currently participating in the XLH Registry) over a 6-month period. Each patient will be followed for up to 12 months after enrolment. As stipulated, the data collection should not require additional patient visits or data collection within the health service.
Three types of data will be used in this study:
- Routinely collected data from the XLH Registry on patient demographics and clinical data, as well as PedsQL HRQoL data.
- HRQoL data prospectively collected at enrolment, 6-month and 12-month follow-up by the patient and/or their parent / legal guardian.
- RSS scores within the XLH Registry will be used where available, or RSS will be centrally calculated retrospectively from radiographs of the affected wrist and/or knee. All RSS calculations will be centrally reviewed.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Edinburgh, United Kingdom, EH9 1LF
- Royal Hospital for Sick Children
-
Glasgow, United Kingdom, G12 0XH
- NHS Greater Glasgow & Clyde- South Glasgow University Hosp Division
-
Leeds, United Kingdom, LS9 7TF
- Leeds Teaching Hospitals NHS Trust, Trust Headquarters, St. James's University Hospital
-
London, United Kingdom, SE1 7EH
- Evelina Childrens Hospital
-
Manchester, United Kingdom, M13 9WL
- Royal Manchester Children's Hospital
-
Sheffield, United Kingdom, S10 2RX
- Sheffield Childrens Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
The study will aim to enrol approximately 50 patients from at least 5 UK centres (currently participating in the XLH Registry).
Subjects will be receiving any XLH treatment (burosumab, oral phosphate and active vitamin D or another XLH treatment) within 30 days or prior to informed consent.
Description
Inclusion Criteria:
- Aged ≥4 years and <18 years.
- Enrolled in the XLH Registry via one of the participating UK centres.
Have at least one of the following:
- RSS calculated at enrolment during a routine clinic visit. OR
- Historical radiographs of the affected wrist and/or knee available in the medical chart within the 6 months prior to enrolment, to allow RSS to be centrally calculated retrospectively.
- Receiving any XLH treatment (burosumab, oral phosphate and active vitamin D, or other XLH treatment) within 30 days prior to informed consent for this study
Exclusion Criteria:
- Does not have the cognitive capacity to provide informed consent, or their legally designated representative (i.e. parent / legal guardian) does not have the cognitive capacity to provide informed consent.
- Is not expected to have open growth plates for the duration of the study.
- Currently participating in an interventional clinical trial. Participation in a Compassionate Use Programme, Pre-commercial Programme, or Investigator Initiated Study does not preclude a patient from participation in this study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To derive health state utilities based on Rickets Severity Score (RSS), in the study population
Time Frame: Changes from baseline, 6 months and 12 months
|
The RSS is a quantitative method to assess rickets severity in the wrists and knees based on the degree of metaphyseal fraying, concavity, and the proportion of the growth plate affected.
It is a 10-point scale, where 10 represents the most extreme degree of rickets severity.
In nutritional rickets, RSS may range from 0.5 to 10.
|
Changes from baseline, 6 months and 12 months
|
To derive health state utilities based on EQ-5D-Y in the study population
Time Frame: Changes from baseline, 6 months and 12 months
|
The EQ-5D-Y is a two-part instrument: the EQ-5D descriptive system and the EQ visual analogue scale (VAS).
The descriptive system covers five health domains: mobility, looking after myself, doing usual activities, having pain or discomfort and feeling worried, sad or unhappy.
Each domain has 3 response categories: no problems, some problems and a lot of problems.
The response categories can be reflected by a 1-digit number (1-3) and combined for the five dimensions into a 5-digit number to describe the health state of the patient.
The EQ VAS records the patient's self-rated health on a vertical VAS of 0-100 where 100="The best health you can imagine" and 0="The worst health you can imagine".
The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement; results can be presented as both a measure of the central tendency and a measure of dispersion.
|
Changes from baseline, 6 months and 12 months
|
To derive health state utilities based on Child Health Utility 9 Dimensions [CHU-9D], in the study population
Time Frame: Changes from baseline, 6 months and 12 months
|
CHU-9D is a generic child HRQoL questionnaire consisting of nine items, each with five response categories.
Each item covers a different domain: worry, sadness, pain, tiredness, annoyance, school, sleep, daily routine and activities.
|
Changes from baseline, 6 months and 12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Nutrition Disorders
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Bone Diseases
- Metabolism, Inborn Errors
- Bone Diseases, Metabolic
- Renal Tubular Transport, Inborn Errors
- Calcium Metabolism Disorders
- Metal Metabolism, Inborn Errors
- Phosphorus Metabolism Disorders
- Rickets
- Vitamin D Deficiency
- Rickets, Hypophosphatemic
- Hypophosphatemia, Familial
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Familial Hypophosphatemic Rickets
- Hypophosphatemia
Other Study ID Numbers
- 2020-55-UK-CRY
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on X-Linked Hypophosphataemia
-
National Eye Institute (NEI)Active, not recruiting
-
National Eye Institute (NEI)CompletedRetinoschisis | X-LinkedUnited States
-
West China HospitalRecruiting
-
University of MiamiJackson Health SystemNo longer available
-
Newcastle-upon-Tyne Hospitals NHS TrustRecruitingX-linked Myotubular Myopathy | Centronuclear Myopathy | Myotubular Myopathy | Myotubular Myopathy 1 | Myotubular (Centronuclear) Myopathy | Centronuclear Myopathy, X-LinkedUnited Kingdom
-
Retina Foundation of the SouthwestDSM Nutritional Products, Inc.; Foundation Fighting BlindnessCompletedRetinitis Pigmentosa | X-linked Genetic DiseasesUnited States
-
Astellas Gene TherapiesCompletedX-linked Myotubular MyopathyUnited States, France, United Kingdom, Canada, Germany
-
University of FloridaAudentes TherapeuticsCompletedX-linked Myotubular MyopathyUnited States
-
Great Ormond Street Hospital for Children NHS Foundation...UnknownX-linked Severe Combined ImmunodeficiencyUnited Kingdom
-
James DowlingCanadian Institutes of Health Research (CIHR); Cures Within Reach; The Joshua... and other collaboratorsRecruitingX Linked Myotubular MyopathyUnited Kingdom, Canada, United States